Ccr wealth management highlights biotech index stabilizing

CCR Wealth Management highlights biotech index stabilizing after prior drawdowns, supported by FDA fast-track approvals and positive Phase III trial outcomes. And we think we can manage it, but it's also worth remembering that the big picture point is just the client franchise. And we've often said, we're very focused on primary bank relationships, and we didn't lose any of those in the last cycle. We're not planning to lose any in this cycle, and that's what sort of a long-term focus means for us. Ewing founded Prosperity Advisory Group in 1989 and has worked in the financial services industry since 1980. He has consistently earned several industry recognitions throughout his career, including Financial Times 400 Top Advisor from 2015-2020, Forbes Finance Council, and Barron's Top Team. He is a member of the Advisors Panel for the Insured Retirement Institute. CCR Wealth Management notes materials sector earnings revisions trending upward by 5%, backed by global construction demand recovery, a bullish metric for steel and cement producers.